Coxibs, cyclo-oxygenase inhibitors;Koxiby, inhibítory cyklooxygenázy

Farmaceuticky Obzor

Volumn 70, Issue 1-2, 2001, Pages 41-45

  Springer V ^a   Chalabala, M ^a  

^a Department of Pharmaceutical Analysis and Nuclear Pharmacy   (Slovakia)

Author keywords

Antiinflammatory drugs; Antirheumatics; Celecoxib; COX 1 inhibitors; COX 2 inhibitors; Coxibs; Rofecoxib

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; MELOXICAM; ROFECOXIB;

ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; ENZYME BINDING; ENZYME INHIBITION; HUMAN; INHIBITION KINETICS; RHEUMATIC DISEASE; SHORT SURVEY; SIDE EFFECT;

EID: 18244425188     PISSN: 00148172     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (22)

1. COX-2 Inhibitoren. Aktueller Stand und Ausblick
2. COX-2 inhibitors
3. Celecoxib Selektiver COX-2 Hemmer
4. Celecoxib ist für den Magen besser als Diclofenac
5. Celecoxib und Rofecoxib sind magenverträglicher als konventionelle NSAR
6. Cyclooxygenase-2 inhibition by rofecoxib reveses naturally occuring fever in humans
7. Rofecoxib gegen Rheumaschmerz
8. Ekonomicke aspekty výskumu a produkcie liečiv a liekov
9. The 500 prescription drugs by worldwide sales
10. Brand of the year
11. Characterization of rofecoxib as a cyclogenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
12. Analgesic efticacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized,controlled trial
13. Update on the coxibs
14. Both COX-2 inhibitors twice as safe as NSAIs, but different they?
15. Pharmacia files parecoxib NDA
16. Products in the pipeline by phase of development
17. COX-3 a new target